CDA | Evidence Driven
CDA | Evidence Driven

enzalutamide

Details

Files
Generic Name:
enzalutamide
Project Status:
Open for Stakeholder Input
Therapeutic Area:
Genito-urinary cancer (prostate cancer)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0366-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)

Files

Proposed Project Scope View PDF
Last Updated : May 1, 2024